Compare Automatic Data Processing Inc (ADP) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Automatic Data Processing Inc vs BioNTech SE - ADR — how do they compare? Automatic Data Processing Inc trades at $268.71 (market cap $107.69B), while BioNTech SE - ADR trades at $93.34 (market cap $23.31B). The key difference: Automatic Data Processing Inc is far larger — about 4.6× BioNTech SE - ADR's market cap, and Automatic Data Processing Inc pays a 2.51% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| ADP | BNTX | |
|---|---|---|
Market Cap | $107.69B | $23.31B |
Sector | Industrials | Health |
52-Week High | $309.03 | $119.34 |
52-Week Low | $188.79 | $83.89 |
Enterprise Value | $108.73B | $6.60B |
Dividend Yield | 2.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $273.68, up 0.87% today, near its consensus price target of $280.50. The stock shows bullish technical signals with strong moving averages and support at $270. Recent quarterly earnings consistently beat estimates, with Q2 2026 EPS of $2.64 surpassing the $2.59 forecast. Revenue growth is steady, reaching $20.56 billion in 2025, with a net income margin of 20.11% and robust ROE of 72.24%.
Outlook remains positive given earnings momentum and dividend stability, but high valuation multiples (P/E 24.78, P/S 4.98) pose risks if growth slows. Analyst sentiment is mixed with 63.89% hold ratings, reflecting caution amid elevated prices. Key risks include labor market sensitivity and competitive pressures in payroll processing.
BioNTech (BNTX) trades at $92.80, down 0.93% on the day, reflecting ongoing pressure from declining COVID-19 vaccine revenue. The stock shows a bullish technical signal from moving averages but faces fundamental headwinds with a net loss of $1.14 billion in 2025 and negative profit margins. Recent Q2 2026 earnings missed expectations, and the company lowered its full-year sales outlook due to soft vaccine demand. Analyst consensus remains strongly bullish with a $121 price target, betting on the long-term potential of its oncology pipeline.
The investment case hinges on BioNTech's transition from COVID-19 vaccines to its deep oncology pipeline, valued near zero given its cash-rich balance sheet. Near-term risks include persistent earnings losses and volatile vaccine revenue, but the company's strong liquidity position and 14 pivotal clinical trials offer substantial upside if pipeline successes materialize. Investors are essentially getting the oncology assets for free, but execution risk is high.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
